KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

PURPOSE: We examined the prognostic impact of specific KRAS mutations in stage III colon adenocarcinoma patients receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF-wild type tumors, since BRAF mutation was associated with poor pro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yoon, Harry H., Tougeron, David, Shi, Qian, Alberts, Steven R., Mahoney, Michelle R., Nelson, Garth D., Nair, Suresh G., Thibodeau, Stephen N., Goldberg, Richard M., Sargent, Daniel J., Sinicrope, Frank A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4040326/
https://ncbi.nlm.nih.gov/pubmed/24687927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados